{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:52:31Z","timestamp":1768582351298,"version":"3.49.0"},"reference-count":21,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":4968,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1999,8]]},"abstract":"<jats:p>The lipophilic beta\u2010adrenoreceptor antagonist propranolol has been studied to define its pharmacokinetic and pharmacodynamic characteristics in hyperlipidemic patients. A total of 48 subjects were allocated to four study groups: (1) healthy volunteers, (2) hypercholesterolemic patients, (3) hypertriglyceridemic subjects, and (4) patients with a mixed form of hyperlipidemia. Propranolol was given orally as a single dose of 80 mg. Heart rate was measured during 12 hours. At each point, the concentrations of propranolol were estimated. Moreover, heart rate and arterial systolic blood pressure were examined at rest and after a submaximal exercise test 3 hours after administration of propranolol (i.e., at the peak of propranolol concentration in the blood serum). A significant increase in the area under the serum concentration\u2010time curve (AUC) by 39% and a reduction of the volume of distribution and total body clearance by 48% and 46%, respectively, without a significant change in the half\u2010life time, were observed in patients with hypertriglyceridemia in comparison with the control group. The acceleration of exercise heart rate and the elevation of systolic blood pressure were comparable in all groups in the study, whereas blood serum concentrations of propranolol in patients with hypertriglyceridemia (group 3) and the mixed form of hyperlipidemia (group 4) were markedly altered from those observed in normolipemic subjects. No relationship between the concentration of propranolol and the heart rate in the group with hypertriglyceridemia was seen. In the light of this study, the authors suggest that lipid metabolism disturbances do not affect the pharmacodynamics of propranolol.<\/jats:p>","DOI":"10.1177\/00912709922008498","type":"journal-article","created":{"date-parts":[[2003,7,19]],"date-time":"2003-07-19T09:38:13Z","timestamp":1058607493000},"page":"826-833","source":"Crossref","is-referenced-by-count":17,"title":["Studies on the Pharmacokinetics and Pharmacodynamics of Propranolol in Hyperlipidemia"],"prefix":"10.1002","volume":"39","author":[{"given":"Jerzy","family":"W\u00f3jcicki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violetta","family":"Sul\u017cyc\u2010Bielicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Kutrzeba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Gawro\u0144ska\u2010Szklarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Dro\u017adzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zozalia","family":"Sterna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"85","article-title":"Antihypertensive drug therapy in relation to lipid disorders","volume":"55","author":"Kawecka\u2010Jaszcz K","year":"1998","journal-title":"Przegl Lek"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0928-0987(95)00024-0"},{"key":"e_1_2_1_4_2","first-page":"63","article-title":"Digoxin pharmacokinetics and echocardiographic evaluation of drug action in patients with hyperlipidemia","volume":"5","author":"Gawro\u0144ska\u2010Szklarz B","year":"1994","journal-title":"Prob Ter Monit"},{"key":"e_1_2_1_5_2","first-page":"844","article-title":"Pharmacokinetics of procainamide in hyperlipidemia","volume":"48","author":"Kutrzeba J","year":"1993","journal-title":"Pol Tyg Lek"},{"key":"e_1_2_1_6_2","first-page":"991","article-title":"Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia","volume":"35","author":"W\u00f3jcicki J","year":"1985","journal-title":"Arzneim-Forsch"},{"key":"e_1_2_1_7_2","first-page":"132","article-title":"Determination of debrisoquine and 4\u2010hydroxydebrisoquine in urine in order to determine a hydroxylation phenotype","volume":"5","author":"Kunicki P","year":"1994","journal-title":"Probl Ter Monit"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)81012-9"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1975184377"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.82"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016345504153"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.78"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315416"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1993.tb04720.x"},{"key":"e_1_2_1_15_2","first-page":"363","volume-title":"Clinical Pharmacology","author":"W\u00f3jcicki J","year":"1993"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.136"},{"key":"e_1_2_1_17_2","first-page":"517","article-title":"The pharmacokinetics of phenytoin in rabbits with hyperlipidemia induced by high\u2010fat diet","volume":"51","author":"Drozdzik M","year":"1994","journal-title":"Acta Pol Pharm"},{"key":"e_1_2_1_18_2","first-page":"299","article-title":"Alteration of drug pharmacodynamics by hyperlipidemia","volume":"218","author":"Candella PJ","year":"1975","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"e_1_2_1_19_2","first-page":"13","article-title":"Efeito da hiperlipidemia experimental na farmacocinetica da procainamida e acecainida","volume":"30","author":"Gawro\u0144ska\u2010Szklarz B","year":"1994","journal-title":"Rev Farm Bioquim Univ S Paulo"},{"key":"e_1_2_1_20_2","first-page":"271","article-title":"Effect of experimental hyperlipidemia on the pharmacokinetics of digoxin","volume":"51","author":"Gawro\u0144ska\u2010Szklarz B","year":"1994","journal-title":"Acta Pol Pharm Drug Res"},{"key":"e_1_2_1_21_2","first-page":"445","article-title":"Influence of hyperlipidemia on pharmacokinetic parameters of digoxin in rabbits","volume":"45","author":"Masiakowski J","year":"1988","journal-title":"Acta Polon Pharmaceut"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(00)88536-7"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F00912709922008498","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/00912709922008498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:50:19Z","timestamp":1695865819000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/00912709922008498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["10.1177\/00912709922008498"],"URL":"https:\/\/doi.org\/10.1177\/00912709922008498","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,8]]}}}